View Older Stories View More Recent Stories

Oct 17, 2021 04:20PM Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS
Oct 17, 2021 04:20PM Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS
Oct 14, 2021 04:07PM Biogen (BIIB) to Report Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS at American Neurological Association Annual Meeting
Oct 14, 2021 04:06PM Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS to be Presented at the American Neurological Association Annual Meeting
Oct 14, 2021 04:06PM Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS to be Presented at the American Neurological Association Annual Meeting
Oct 13, 2021 06:05AM New Data at ECTRIMS 2021 Highlight Biogen’s Focus on Patient-Centered Outcomes and Improving the MS Patient Experience
Oct 13, 2021 06:05AM New Data at ECTRIMS 2021 Highlight Biogen’s Focus on Patient-Centered Outcomes and Improving the MS Patient Experience
Oct 13, 2021 06:02AM New Data Confirm Biogen’s (BIIB) Disease-Modifying Therapies Do Not Reduce Antibody Response to COVID-19 Vaccines in People with Multiple Sclerosis
Oct 13, 2021 06:02AM New MS PATHS Data at ECTRIMS 2021 Confirm Biogen’s Disease-Modifying Therapies Do Not Reduce Antibody Response to COVID-19 Vaccines in People with Multiple Sclerosis
Oct 13, 2021 06:02AM New MS PATHS Data at ECTRIMS 2021 Confirm Biogen’s Disease-Modifying Therapies Do Not Reduce Antibody Response to COVID-19 Vaccines in People with Multiple Sclerosis
Oct 4, 2021 06:31AM SAGE Therapeutics (SAGE), Biogen (BIIB) Announce Consistent Clinically Meaningful Data for Zuranolone Across the LANDSCAPE and NEST Clinical Development Programs Presented at ECNP Congress
Oct 4, 2021 06:30AM Sage Therapeutics and Biogen Announce Consistent Clinically Meaningful Data for Zuranolone Across the LANDSCAPE and NEST Clinical Development Programs Presented at the European College of Neuropsychop
Sep 27, 2021 07:30PM Eisai Initiates Rolling Submission To The U.S. FDA For Biologics License Application Of Lecanemab (BAN2401) For Early Alzheimer's Disease Under The Accelerated Approval Pathway
Sep 21, 2021 08:31AM Biogen (BIIB) R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
Sep 21, 2021 08:30AM Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
Sep 21, 2021 08:30AM Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
Sep 20, 2021 07:30AM Biogen (BIIB) and Samsung's BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab-nuna) Approved by FDA
Sep 20, 2021 07:30AM FDA Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab-nuna)
Sep 20, 2021 07:30AM FDA Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab-nuna)
Sep 20, 2021 07:30AM FDA Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab-nuna)
Sep 20, 2021 07:30AM FDA Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab-nuna)
Sep 17, 2021 09:11AM Biogen (BIIB) Announces CHMP Recommends VUMERITY for Approval in the European Union as a Treatment for Relapsing-Remitting MS
Sep 17, 2021 09:09AM CHMP Recommends VUMERITY® (diroximel fumarate) for Approval in the European Union as a Treatment for Relapsing-Remitting Multiple Sclerosis
Sep 17, 2021 09:09AM CHMP Recommends VUMERITY® (diroximel fumarate) for Approval in the European Union as a Treatment for Relapsing-Remitting Multiple Sclerosis
Sep 16, 2021 07:30AM Biogen (BIIB) Announces Positive Results from Phase 2 CONVEY Study in Small Fiber Neuropathy
Sep 16, 2021 07:30AM Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy
Sep 16, 2021 07:30AM Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy
Sep 15, 2021 07:31AM Biogen (BIIB) to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi
Sep 15, 2021 07:30AM Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi® (risdiplam)
Sep 15, 2021 07:30AM Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi® (risdiplam)
Aug 2, 2021 07:32AM Biogen (BIIB) Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting MS
Aug 2, 2021 07:30AM Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis
Aug 2, 2021 07:30AM Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis
Jul 29, 2021 04:30PM Late-Breaking AAIC Presentation Explores Potential Clinical Effects Of Lecanemab (BAN2401)
Jul 29, 2021 04:10PM Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer’s Disease at AAIC 2021
Jul 29, 2021 04:10PM Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer’s Disease at AAIC 2021
Jul 26, 2021 04:36PM Biogen (BIIB), Ionis (IONS) report positive topline clinical data on investigational Alzheimer's disease treatment at AAIC
Jul 26, 2021 04:35PM Biogen and Ionis report positive topline clinical data on investigational Alzheimer's disease treatment at AAIC
Jul 26, 2021 04:13PM Biogen (BIIB), Eisai Announce ADUHELM Data Presentations at Alzheimer’s Association International Conference 2021
Jul 26, 2021 04:10PM Biogen and Eisai Announce ADUHELM™ (aducanumab-avwa) Data Presentations at Alzheimer’s Association International Conference 2021
Jul 26, 2021 04:10PM Biogen and Eisai Announce ADUHELM™ (aducanumab-avwa) Data Presentations at Alzheimer’s Association International Conference 2021
Jul 23, 2021 04:30PM Biogen (BIIB) to Present Data from ADUHELM and Alzheimer’s Disease Portfolio at 2021 Alzheimer’s Association International Conference
Jul 23, 2021 04:30PM Biogen to Present Data from ADUHELM and Alzheimer’s Disease Portfolio at 2021 Alzheimer’s Association International Conference
Jul 23, 2021 04:30PM Biogen to Present Data from ADUHELM and Alzheimer’s Disease Portfolio at 2021 Alzheimer’s Association International Conference
Jul 22, 2021 07:06AM Biogen (BIIB) Head of R&D says ADUHELM’s approval has been the subject of extensive misinformation and misunderstanding
Jul 22, 2021 07:05AM An open letter to the Alzheimer’s disease community from our Head of Research and Development, Alfred Sandrock, M.D., Ph.D.
Jul 22, 2021 07:05AM An open letter to the Alzheimer’s disease community from our Head of Research and Development, Alfred Sandrock, M.D., Ph.D.
Jul 12, 2021 07:00PM Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis
Jul 12, 2021 07:00PM Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis
Jul 9, 2021 02:37PM FDA seeks probe into its talks with Biogen before Alzheimer's drug approval
View More Recent Stories View Older Stories